An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

Inclusion Criteria:

• Diagnosis of UC for at least 3 months.
• Inadequate response or intolerance to conventional therapy for the treatment ofulcerative colitis
• Evidence of active UC based on the modified Mayo score
• No known history of active TB
• Agree to practicing abstinence or adhering to specific birth control requirements

Exclusion Criteria:

• Participant has UC limited to the rectum
• History of fulminant colitis, a diagnosis of Crohn's disease or indeterminate colitisspecific complication of UC, including toxic megacolon
• Previous intolerance or non-response to vedolizumab
• Participants receiving exclusionary treatment within specified time periods
• History of cancer, except for basal cell carcinoma, squamous cell carcinoma, orcarcinoma in situ of the cervix.
• Clinically significant infections
• Clinically significant cardiovascular conditions